Sugi Predict

Sugi Predict / Targets / RARB

RARB

Retinoic acid receptor beta · P10826 · RARB on Sugi Atlas →

178,900 patent compounds predicted against RARB, 90,855 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL177444 SCHEMBL177444 1.00 18/20
Tazarotene Tazarotene (SCHEMBL3134) 1.00 15/20
SCHEMBL180433 SCHEMBL180433 0.64 15/20
SCHEMBL165750 SCHEMBL165750 1.00 14/20
SCHEMBL165751 SCHEMBL165751 1.00 14/20
Adapalene Adapalene (SCHEMBL2747) 1.00 13/20
O-Demethylated Adapalene O-Demethylated Adapalene (SCHEMBL174205) 1.00 13/20
SCHEMBL156460 SCHEMBL156460 1.00 12/20
Adapalene Adapalene (SCHEMBL60989) 0.84 12/20
SCHEMBL173380 SCHEMBL173380 0.76 12/20
SCHEMBL177719 SCHEMBL177719 0.73 12/20
SCHEMBL177720 SCHEMBL177720 0.73 12/20
SCHEMBL180442 SCHEMBL180442 0.67 12/20
SCHEMBL163779 SCHEMBL163779 0.70 11/20
SCHEMBL181635 SCHEMBL181635 0.49 11/20
SCHEMBL174449 SCHEMBL174449 0.49 11/20
Tamibarotene Tamibarotene (SCHEMBL36207) 1.00 10/20
SCHEMBL36417 SCHEMBL36417 0.54 10/20
SCHEMBL35985 SCHEMBL35985 0.50 10/20
SCHEMBL75127 SCHEMBL75127 0.50 10/20

Clinical trials — most relevant to RARB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris PHASE4COMPLETED
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis PHASE2/PHASE3COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation PHASE3COMPLETED
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia PHASE3UNKNOWN
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia PHASE3COMPLETED
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS PHASE2/PHASE3UNKNOWN
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL). PHASE3RECRUITING
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis PHASE2UNKNOWN
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. PHASE1/PHASE2UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma PHASE1/PHASE2COMPLETED
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) PHASE2COMPLETED
Phase II 5-Azacytidine Plus VPA Plus ATRA PHASE2COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma PHASE2RECRUITING
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus PHASE2UNKNOWN
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer PHASE1/PHASE2RECRUITING
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid PHASE1UNKNOWN
Oral Clofarabine for Acute Myeloid Leukemia PHASE1COMPLETED
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery PHASE1COMPLETED
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients EARLY_PHASE1RECRUITING
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma EARLY_PHASE1COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes nanCOMPLETED
Retinoic Acid Homeostasis in Neuropsychiatric Diseases nanUNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
ALDH1A1 Expression in Invasive Mammary Carcinoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RARB binder may also engage these)

ProteinNameSimilarity
P18514 — 1.000 P18514 →
Q9W6B3 — 1.000 Q9W6B3 →
P22448 — 1.000 P22448 →
Q9W5Z3 — 1.000 Q9W5Z3 →
P11416 — 1.000 P11416 →
Q90966 — 1.000 Q90966 →
P51126 — 1.000 P51126 →
P22605 — 1.000 P22605 →
Q5FBR4 — 1.000 Q5FBR4 →
RARA Retinoic acid receptor alpha 1.000 landscape →
Q90271 — 0.999 Q90271 →
Q7ZTI3 — 0.997 Q7ZTI3 →
P28699 — 0.994 P28699 →
Q91392 — 0.992 Q91392 →
P18911 — 0.990 P18911 →
A2T928 — 0.988 A2T928 →
RARG Retinoic acid receptor gamma 0.986 landscape →
P18516 — 0.985 P18516 →
Q641K1 — 0.974 Q641K1 →
PI4KB Phosphatidylinositol 4-kinase beta 0.974 landscape →
O08561 — 0.973 O08561 →
B0KWC1 — 0.973 B0KWC1 →
Q6NRE7 — 0.973 Q6NRE7 →
Q8JIR0 — 0.973 Q8JIR0 →
P23798 — 0.972 P23798 →
Q9UPW5 — 0.972 Q9UPW5 →
B1MTG7 — 0.972 B1MTG7 →
P35227 — 0.972 P35227 →
Q9ESL4 — 0.972 Q9ESL4 →
Q69ZT9 — 0.971 Q69ZT9 →